Operating status of Danish Lingbei Pharmaceutical Co., Ltd.

Business scope, annual turnover and operation of the company. In the past ten years, the company has developed well. The reason for the rapid growth of turnover is that the company successfully launched the antidepressant Capraimil/celexa in the American market in cooperation with Forest Company in March 1998. Although the global stock market is in a downturn, the shares of Danish pharmaceutical company Lundbeck A/S seem to stand out, climbing 164% in 2000 and rising 15% in early 2006. According to the analysis, the main reason is that the company's flagship product Capiamil/Celexa sells well. Since Celexa 1998 was put into the American market, it has occupied 14% of the similar drug market, almost equal to Lilly, Pfizer and GlaxoSmithKline. These three world-renowned pharmaceutical companies have a market share of about 24% in the United States.

In Europe, Capiamil/Celexa accounts for about 10% of the market share of similar drugs.

Now the challenge for the company is to successfully bring its replacement product Cipralex to the market before Capiamil's patent expires.

Parent company and subsidiary company information

The company has 30 subsidiaries in European countries, Australia, New Zealand, Canada and South Africa, and is currently preparing a subsidiary in Turkey. In addition, it has representative offices in China, Japan, Pakistan, Singapore, Saudi Arabia, Israel in Asia, Egypt in Africa and the United States.